| Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial F Zoulim, C Fournier, F Habersetzer, M Sprinzl, S Pol, CS Coffin, V Leroy, ... Human Vaccines & Immunotherapeutics 16 (2), 388-399, 2020 | 86 | 2020 |
| A generic operational strategy to qualify translational safety biomarkers K Matheis, D Laurie, C Andriamandroso, N Arber, L Badimon, X Benain, ... Drug discovery today 16 (13-14), 600-608, 2011 | 77 | 2011 |
| Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC C Tosch, B Bastien, L Barraud, B Grellier, V Nourtier, M Gantzer, ... Journal for immunotherapy of cancer 5, 1-10, 2017 | 59 | 2017 |
| BERTMHC: improved MHC–peptide class II interaction prediction with transformer and multiple instance learning J Cheng, K Bendjama, K Rittner, B Malone Bioinformatics 37 (22), 4172-4179, 2021 | 54 | 2021 |
| Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal … C Remy-Ziller, C Thioudellet, J Hortelano, M Gantzer, V Nourtier, ... Human vaccines & immunotherapeutics 14 (1), 140-145, 2018 | 37 | 2018 |
| Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients A Samson, EJ West, J Carmichael, KJ Scott, S Turnbull, B Kuszlewicz, ... Cancer immunology research 10 (6), 745-756, 2022 | 29 | 2022 |
| Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers C Le Tourneau, JP Delord, P Cassier, D Loirat, A Tavernaro, B Bastien, ... Annals of Oncology 30, v494-v495, 2019 | 25 | 2019 |
| Translation strategy for the qualification of drug-induced vascular injury biomarkers K Bendjama, S Guionaud, G Aras, N Arber, L Badimon, U Bamberger, ... Toxicologic pathology 42 (4), 658-671, 2014 | 21 | 2014 |
| Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer K McCann, A von Witzleben, J Thomas, C Wang, O Wood, D Singh, ... Journal for immunotherapy of cancer 10 (3), 2022 | 19 | 2022 |
| Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer K Bendjama, E Quemeneur Human Vaccines & Immunotherapeutics 13 (9), 1997-2003, 2017 | 11 | 2017 |
| 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV … C Le Tourneau, P Cassier, F Rolland, S Salas, JM Limacher, O Capitain, ... Annals of Oncology 31, S1442, 2020 | 7 | 2020 |
| Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. A Anthoney, A Samson, E West, SJ Turnbull, K Scott, E Tidswell, ... Journal of Clinical Oncology 36 (15_suppl), 3092-3092, 2018 | 7 | 2018 |
| Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16 … E Borcoman, A Lalanne, JP Delord, PA Cassier, F Rolland, S Salas, ... European Journal of Cancer 191, 112981, 2023 | 6 | 2023 |
| Intravenous oncolytic vaccinia virus therapy results in a differential immune response between cancer patients EJ West, KJ Scott, E Tidswell, K Bendjama, N Stojkowitz, M Lusky, ... Cancers 14 (9), 2181, 2022 | 6 | 2022 |
| 793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity C Le Tourneau, P Cassier, F Rolland, S Salas, JM Limacher, O Capitain, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 6 | 2020 |
| Roflumilast-induced local vascular injury is associated with a coordinated proteome and microparticle change in the systemic circulation in pigs G Vilahur, J Cubedo, T Padró, L Casaní, O Juan-Babot, J Crespo, ... Toxicologic Pathology 43 (4), 569-580, 2015 | 5 | 2015 |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC). JP Delord, MS Block, C Ottensmeier, G Colon-Otero, C Le Tourneau, ... Journal of Clinical Oncology 40 (16_suppl), 2637-2637, 2022 | 4 | 2022 |
| Correlation of HPV16 gene status and gene expression with antibody seropositivity and TIL status in OPSCC A von Witzleben, E Currall, O Wood, L Chudley, O Akinyegun, J Thomas, ... Frontiers in Oncology 10, 591063, 2021 | 4 | 2021 |
| Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity A Samson, E West, S Turnbull, K Scott, E Tidswell, J Kingston, ... Annals of Oncology 30, v496, 2019 | 4 | 2019 |
| Phase 1b clinical trial of TG1050 a novel HBV-targeted immunotherapy in NUC suppressed chronic hepatitis B (CHB) patients: safety and early immunological data following single … MF Sprinzl, C Fournier, V Leroy, S Pol, F Habersetzer, R Thimme, MM Ma, ... Hepatology 66, 483A-484A, 2017 | 4 | 2017 |
